The patent application WO2015083071, filed in 2015, relates to daridorexant [1]. This application is available through Google Patents [1].
What is Daridorexant Used For?
Daridorexant is a dual orexin receptor antagonist developed for the treatment of insomnia [2]. Orexin is a neurotransmitter involved in promoting wakefulness, and by blocking its receptors, daridorexant aims to reduce arousal and facilitate sleep [2][3].
When Does the Daridorexant Patent Expire?
Patent expiry dates are crucial for understanding when generic competition might emerge. Information on the specific expiry of patents related to daridorexant can be found on specialized databases [4]. For example, the patent family associated with WO2015083071 may have multiple patents with different expiry dates, depending on the countries of filing and any granted extensions [4]. DrugPatentWatch.com provides resources for tracking these patent expiries [4].
Who Makes Daridorexant?
Daridorexant is developed and marketed by Idorsia Pharmaceuticals [2].
How Does Daridorexant Work?
Daridorexant functions by inhibiting the binding of orexin-A and orexin-B to their receptors (OX1R and OX2R) [3]. This dual antagonism reduces the signaling pathways that promote wakefulness, thus helping to initiate and maintain sleep [3].
What Are the Potential Side Effects of Daridorexant?
Common side effects reported for daridorexant include somnolence, headache, and fatigue [2]. The drug carries a warning for potential sleep paralysis and hypnagogic/hypnopompic hallucinations, which can occur if the drug is taken under conditions where full nighttime sleep is not possible or upon waking [2].
How Does Daridorexant Compare to Other Insomnia Treatments?
Daridorexant represents a different pharmacological class compared to traditional hypnotics like benzodiazepines or Z-drugs. It targets the wakefulness system directly, rather than acting as a general central nervous system depressant [3]. This mechanism is believed to offer a different benefit-risk profile, potentially with less risk of dependence or withdrawal symptoms compared to older drug classes [3].
What Clinical Data Supports Daridorexant's Efficacy?
Clinical trials have demonstrated that daridorexant effectively improves sleep onset and sleep maintenance in adults with moderate to severe insomnia [2][3]. Studies have shown reductions in wake after sleep onset and improvements in total sleep time, with efficacy observed across different age groups [2][3].
Are There Any Risks Associated with Daridorexant?
In addition to the side effects mentioned, daridorexant carries a warning for potential central nervous system depression, which can impair driving and other activities requiring alertness [2]. It should not be taken with alcohol or other sedating medications [2].
What is the Regulatory Status of Daridorexant?
Daridorexant has received regulatory approval in several regions. It was approved by the U.S. Food and Drug Administration (FDA) in January 2022 and by the European Medicines Agency (EMA) in 2023 [2].
Sources:
[1] https://patents.google.com/patent/WO2015083071A1/
[2] https://www.drugpatentwatch.com/drug/daridorexant
[3] https://www.drugpatentwatch.com/drug/daridorexant/mechanism-of-action
[4] https://www.drugpatentwatch.com/